Adult Outcomes for Juvenile Idiopathic Arthritis Show Continued Need for Biologic Therapies

Patients with juvenile idiopathic arthritis (JIA) who transition to adult rheumatology care frequently require continued biologic therapies, according to a retrospective study published in Clinical Rheumatology. The research highlights varying treatment patterns and disease burdens among different JIA subtypes as patients move into adulthood.

Understanding Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis is a group of chronic arthritides that begin in childhood. Initial management typically involves nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular glucocorticoids, and conventional disease-modifying antirheumatic drugs (DMARDs). However, ongoing disease activity is common as patients age, necessitating continued rheumatologic care American College of Rheumatology.

Study Details and Findings

Researchers at Hacettepe University in Turkey conducted a retrospective analysis using data from the HUR-BIO registry, a single-center biologic repository. The study included 172 patients diagnosed with JIA before the age of 16 who were followed in adult rheumatology care between 2005 and 2022. Patients were categorized based on the International League of Associations for Rheumatology (ILAR) criteria.

The most common JIA subtype among the 167 patients analyzed was enthesitis-related arthritis (ERA), affecting 49.1% (n=82), followed by polyarticular JIA at 38.9% (n=65). Tumor necrosis factor (TNF) inhibitors were the primary first-line biologic treatment for 97% of patients (n=162), with etanercept being the most frequently used (62.9%, n=105), followed by adalimumab (16.8%, n=28) and infliximab (12.6%, n=21).

Over a mean follow-up period of 9.9±0.6 years, 58% of patients required at least one biologic switch, with secondary failure being the reason for 43.3% of these changes. At the last follow-up, 64.7% of patients achieved remission, defined as a Disease Activity Score 28 with erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6.

Subtype-Specific Disease Burden

The study revealed differences in clinical burden based on JIA subtype. Before initiating biologic therapy, patients with polyarticular JIA exhibited significantly higher mean DAS28-ESR values (4.7 vs 3.0; P < .001), higher Health Assessment Questionnaire (HAQ) scores (1.2 vs 0.6; P =.020), and a longer time to biologic initiation (11.2 vs 5.0 years; P < .001) compared to those with ERA.

Surgical interventions also differed between subtypes. Hip arthroplasty was required in 18.5% of patients with polyarticular JIA, compared to only 1.2% of those with ERA (P < .001).

Study Limitations and Future Research

The researchers acknowledged several limitations, including the retrospective, single-center design, incomplete prebiologic clinical data, and variations within JIA subgroups. These factors may influence the analysis of disease severity and treatment response.

The study authors concluded that “more extensive prospective studies are needed to understand better how JIA progresses in adulthood and how its course varies across different subgroups.” 2021 American College of Rheumatology Guideline.

Key Takeaways

• Adults with JIA frequently require continued biologic therapies.
• TNF inhibitors are the predominant first-line biologic treatment.
• Disease burden and treatment needs vary significantly based on JIA subtype.
• Further research is needed to optimize long-term management of JIA in adults.